MLTX 4-DAY DEADLINE ALERT: MoonLake (MLTX) Class Action Lawsuit – Hagens Berman Scrutinizing Nanobody Superiority Claims After 90% Plunge; December Lead Plaintiff Deadline Looms

Core Viewpoint - A securities class action lawsuit has been filed against MoonLake Immunotherapeutics, alleging that the company and its executives made materially false and misleading statements about the clinical prospects of their drug candidate, sonelokimab (SLK), leading to a nearly 90% stock crash following disappointing Phase 3 trial results [2][3][4]. Summary by Relevant Sections Lawsuit Allegations - The lawsuit claims that MoonLake misrepresented the efficacy of SLK, asserting that its unique Nanobody structure would provide superior clinical outcomes compared to traditional monoclonal antibodies, specifically against the FDA-approved competitor BIMZELX [3][4]. Stock Performance - Following the announcement of the VELA-2 trial results, which failed to meet its primary endpoint and demonstrated inferior efficacy compared to competitors, MoonLake's stock plummeted from $61.99 to $6.24, marking a 90% loss on September 29, 2025 [4]. Investor Actions - Investors who purchased MoonLake stock between March 10, 2024, and September 29, 2025, and experienced significant losses are encouraged to contact Hagens Berman to discuss their legal options and potential appointment as Lead Plaintiff [6][7]. Important Dates - The Lead Plaintiff Deadline for the lawsuit is December 15, 2025, which is rapidly approaching [1][6].